Progyny (PGNY) Expected to Announce Earnings on Tuesday

Progyny (NASDAQ:PGNY) is expected to be posting its quarterly earnings results after the market closes on Tuesday, February 25th. Analysts expect Progyny to post earnings of $0.36 per share and revenue of $277.31 million for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

Progyny Trading Down 2.8 %

Shares of NASDAQ PGNY opened at $23.20 on Monday. The stock has a market capitalization of $1.98 billion, a PE ratio of 40.00, a price-to-earnings-growth ratio of 2.39 and a beta of 1.34. Progyny has a 12-month low of $13.39 and a 12-month high of $40.89. The stock’s fifty day simple moving average is $19.84 and its two-hundred day simple moving average is $18.60.

Insider Buying and Selling

In other Progyny news, CEO Peter Anevski bought 209,500 shares of Progyny stock in a transaction on Monday, December 23rd. The shares were bought at an average price of $14.48 per share, for a total transaction of $3,033,560.00. Following the completion of the transaction, the chief executive officer now directly owns 441,463 shares of the company’s stock, valued at $6,392,384.24. This trade represents a 90.32 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Chairman David J. Schlanger acquired 150,000 shares of Progyny stock in a transaction that occurred on Thursday, December 26th. The stock was bought at an average price of $14.68 per share, for a total transaction of $2,202,000.00. Following the completion of the acquisition, the chairman now owns 228,269 shares in the company, valued at $3,350,988.92. This trade represents a 191.65 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on PGNY shares. Bank of America lifted their price objective on shares of Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, February 11th. JPMorgan Chase & Co. raised their price objective on Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 28th. Canaccord Genuity Group cut their price target on shares of Progyny from $18.00 to $17.00 and set a “hold” rating on the stock in a research note on Wednesday, November 13th. Barclays dropped their price objective on shares of Progyny from $30.00 to $17.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. Finally, Truist Financial reissued a “hold” rating and issued a $19.00 target price (down from $26.00) on shares of Progyny in a research report on Wednesday, November 13th. Nine research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $25.83.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.